Sarepta Therapeutics Stock Surges 43 percent YTD How to Play the Stock?
| ARWR Stock | USD 19.56 0.54 2.84% |
Slightly above 55% of Arrowhead Pharmaceuticals' retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Arrowhead Pharmaceuticals suggests that some traders are interested. Arrowhead Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Arrowhead Pharmaceuticals. Many technical investors use Arrowhead Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Arrowhead |
The rise in SRPTs share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.
Read at zacks.com
 |
Arrowhead Pharmaceuticals Fundamental Analysis
We analyze Arrowhead Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arrowhead Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arrowhead Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Arrowhead Pharmaceuticals is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Arrowhead Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Arrowhead Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Arrowhead Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Arrowhead Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Arrowhead Pharmaceuticals Related Equities
| BPMC | Blueprint Medicines | 5.87 | ||||
| PRQR | ProQR Therapeutics | 3.04 | ||||
| AMLX | Amylyx Pharmaceuticals | 2.86 | ||||
| ANNX | Annexon | 2.19 | ||||
| DAWN | Day One | 1.13 | ||||
| APLS | Apellis Pharmaceuticals | 0.71 | ||||
| ASMB | Assembly Biosciences | 0.49 | ||||
| BMRN | Biomarin Pharmaceutical | 0.46 | ||||
| INCY | Incyte | 0.75 | ||||
| CTMX | CytomX Therapeutics | 1.18 | ||||
| TERN | Terns Pharmaceuticals | 1.56 | ||||
| IONS | Ionis Pharmaceuticals | 2.63 | ||||
| WVE | Wave Life | 2.83 |
Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.